J. Korth-Bradley

发表

A Pilot Dose‐Finding Study of Etanercept in Rheumatoid Arthritis

F. Breedveld, H. Jones, Kim Peifer, 2017, Clinical and translational science.

Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis

T. Bjornsson, J. Korth-Bradley, S. Fatenejad, 2011, Journal of clinical pharmacology.

Population Pharmacokinetics of Intravenous Amiodarone and Comparison with Two‐Stage Pharmacokinetic Analysis

S. Troy, J. Korth-Bradley, K. Vadiei, 1997, Journal of clinical pharmacology.

Pharmacokinetic and Pharmacodynamic Action of Etodolac in Patients after Oral Surgery

J. Boni, J. Korth-Bradley, A. Appel, 1999, Journal of clinical pharmacology.

Licensure of Gemtuzumab Ozogamicin for the Treatment of Selected Patients 60 Years of Age or Older with Acute Myeloid Leukemia in First Relapse

M. Berger, J. Korth-Bradley, L. Leopold, 2002, Investigational New Drugs.

Impact of Age and Gender on the Pharmacokinetics of Gemtuzumab Ozogamicin

M. Berger, J. Korth-Bradley, S. P. King, 2001, Pharmacotherapy.

A Casting Call from Industry: Reel in and Retain Appropriate Information, Release the Rest

J. Korth-Bradley, J. Oki, J. F. Mouser, 2002, Pharmacotherapy.

The Path to Perfect Pediatric Posology — Drug Development in Pediatrics

J. Korth-Bradley, 2018, Journal of clinical pharmacology.

Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating Women

Kyle T. Matschke, J. Korth-Bradley, P. Bryson, 2011, Antimicrobial Agents and Chemotherapy.

Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis.

M. Sharland, M. Wible, J. Korth-Bradley, 2019, The Pediatric infectious disease journal.

Tigecycline Pharmacokinetics in Subjects With Various Degrees of Renal Function

S. Troy, R. Fruncillo, Kyle T. Matschke, 2012, Journal of clinical pharmacology.

Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa

J. Korth-Bradley, J. Fuiman, Lynne Smith, 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Pharmacokinetics of Gemtuzumab Ozogamicin as a Single‐Agent Treatment of Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

J. Korth-Bradley, B. Gorovits, J. Dowell, 2004, Journal of clinical pharmacology.

Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis

A. Patat, M. Morgan, C. Gleiter, 2011, Journal of clinical pharmacology.

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

E. Neufeld, A. Iorio, J. Blatny, 2018, Research and practice in thrombosis and haemostasis.

Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

Arthur J. L. Cooper, J. Korth-Bradley, S. Bhavnani, 2011, Antimicrobial Agents and Chemotherapy.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

B. Cirincione, J. Korth-Bradley, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Randomized Phase 2 Trial To Evaluate the Clinical Efficacy of Two High-Dosage Tigecycline Regimens versus Imipenem-Cilastatin for Treatment of Hospital-Acquired Pneumonia

J. Ramirez, J. Korth-Bradley, J. Yan, 2013, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections

E. Ludwig, B. Cirincione, J. Korth-Bradley, 2006, Antimicrobial Agents and Chemotherapy.

The pharmacokinetics of etanercept in patients with heart failure.

D. Mann, A. Feldman, V. M. Schneider, 2001, British journal of clinical pharmacology.

The Pharmacokinetics of Etanercept in Healthy Volunteers

D. Simcoe, J. Korth-Bradley, R. Hanna, 2000, The Annals of pharmacotherapy.

Drug–Drug Interactions for Etanercept—A Fusion Protein

J. Korth-Bradley, 2013 .

The Comparability of Etanercept Pharmacokinetics in Healthy Japanese and American Subjects

J. Korth-Bradley, S. Kawai, S. Tsuchiwata, 2006, Journal of clinical pharmacology.

Lack of Effect of Rivipansel on QTc Interval in Healthy Adult African American Male Subjects

J. Korth-Bradley, A. Płotka, B. Tammara, 2017, Journal of clinical pharmacology.

A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients

G. Russ, A. Hartmann, F. Schena, 2013, Transplantation.

Factors that influence the bleeding phenotype in severe hemophilic patients

J. Korth-Bradley, P. Rendo, F. Shafer, 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Population Pharmacokinetics of Intravenous Amiodarone in Patients with Refractory Ventricular Tachycardia/Fibrillation

J. Korth-Bradley, J. Peters, S. Chiang, 1996, Journal of clinical pharmacology.

Evaluating Possible Pharmacokinetic Interactions between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients with Various Degrees of Renal Impairment

J. Korth-Bradley, Susanna Tse, J. Dowell, 2001, Journal of clinical pharmacology.

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics

B. Meibohm, M. Mandić, J. Korth-Bradley, 2017, Journal of clinical pharmacology.

Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

F. Schena, J. Campistol, J. Korth-Bradley, 2011, Transplantation.

Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2012, Clinical pharmacology in drug development.

The Effect of a High-Fat Breakfast on the Pharmacokinetics of Moxidectin in Healthy Male Subjects: A Randomized Phase I Trial

Kyle T. Matschke, J. Korth-Bradley, S. Chalon, 2012, The American journal of tropical medicine and hygiene.

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2013, European Journal of Clinical Pharmacology.

Understanding the Placebo Effect in Complementary Medicine: Theory, Practice and Research

J. Korth-Bradley, 2002 .

Steady‐state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients

J. Korth-Bradley, Xiongfei Wu, F. Qiu, 2014, Clinical pharmacology in drug development.

The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers

K. Lasseter, Kyle T. Matschke, J. Korth-Bradley, 2014, Clinical pharmacology in drug development.

The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

A. Patat, Kyle T. Matschke, J. Korth-Bradley, 2013, European Journal of Clinical Pharmacology.

Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel

J. Korth-Bradley, A. Płotka, B. Tammara, 2020, Clinical pharmacology in drug development.

Chiral Bioequivalence

L. Benet, J. Boni, L. Richards, 2000, Clinical pharmacokinetics.

Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

L. Valentino, J. Korth-Bradley, I. Elezović, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia

J. Korth-Bradley, A. Shapiro, M. Poon, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B

J. Korth-Bradley, Y. Tomono, A. Suzuki, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.

J. Korth-Bradley, C. Altisent, Lynne Smith, 2016, Clinical therapeutics.

Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B

K. Kuliczkowski, J. Korth-Bradley, K. Kavaklı, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia

Arthur J. L. Cooper, J. Korth-Bradley, S. Bhavnani, 2010, Antimicrobial Agents and Chemotherapy.

Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

J. Korth-Bradley, K. Rodvold, M. Gotfried, 2006, The Journal of antimicrobial chemotherapy.

Reassessment of tigecycline bone concentrations in volunteers undergoing elective orthopedic procedures

J. Korth-Bradley, I. Bhattacharya, A. Ji, 2014, Journal of clinical pharmacology.

Elucidation of Factor VIII Activity Pharmacokinetics: A Pooled Population Analysis in Patients With Hemophilia A Treated With Moroctocog Alfa

S. Jönsson, L. Harnisch, J. Korth-Bradley, 2017, Clinical pharmacology and therapeutics.

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A

J. Korth-Bradley, A. Płotka, P. Rendo, 2018, Clinical and translational science.

Clinical experience with moroctocog alfa (AF‐CC) in younger paediatric patients with severe haemophilia A: Two open‐label studies

J. Korth-Bradley, K. Kavaklı, J. Fuiman, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.

P. Hu, S. Nepal, Yali Liang, 2017, Clinical therapeutics.

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Mark P Smith, J. Korth-Bradley, Y. Wali, 2018, Blood.

Evaluation of Two Secondary Prophylaxis Regimens of Recombinant Factor IX(r-IX) in Moderately Severe to Severe( FIX ≤2%) Hemophilia B Patients

J. Korth-Bradley, Lynne Smith, P. Rendo, 2012 .

Once-weekly prophylaxis regimen of nonacog alfa in patients with hemophilia B: an analysis of timing of bleeding event onset

M. Carr, B. Tortella, J. Korth-Bradley, 2021, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B

R. Labadie, J. Korth-Bradley, R. Wu, 2017, Thrombosis and Haemostasis.

Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings

V. Jiménez‐Yuste, J. Korth-Bradley, A. Cid, 2015, Thrombosis and Haemostasis.

Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B

K. Kuliczkowski, J. Korth-Bradley, K. Kavaklı, 2014 .

First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China

J. Korth-Bradley, R. Wu, Lihong Xu, 2021, Medicine.

Assessment of relative bioavailability of two presentations of moroctocog alfa (AF‐CC) in subjects with moderately severe or severe hemophilia A

Yali Liang, J. Korth-Bradley, A. Płotka, 2015, Clinical pharmacology in drug development.

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies

Jie Jin, Depei Wu, J. Korth-Bradley, 2020, Journal of blood medicine.

Translational Research: Preclinical to Healthy Volunteer to Patient

J. Korth-Bradley, S. Raje, B. Tammara, 2017 .

Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.

J. Korth-Bradley, J. Yan, N. Dartois, 2012, Clinical therapeutics.

Intervals in Healthy Subjects Tigecycline Does Not Prolong Corrected QT

Kyle T. Matschke, J. Korth-Bradley, A. Płotka, 2014 .

Tigecycline Does Not Prolong Corrected QT Intervals in Healthy Subjects

Joanne Salageanu, Kyle T. Matschke, J. Korth-Bradley, 2013, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetics of Tigecycline in Healthy Volunteers

E. Ludwig, B. Cirincione, J. Korth-Bradley, 2007, Journal of clinical pharmacology.

- 1-Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-abdominal or Skin and Skin-Structure Infections

E. Ludwig, B. Cirincione, J. Korth-Bradley, 2006 .

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

E. Raymond, J. Armand, S. Faivre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

Y. Chuang, J. Korth-Bradley, N. Dartois, 2010, Diagnostic microbiology and infectious disease.

Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation

G. Drusano, J. Korth-Bradley, S. Bhavnani, 2007, Antimicrobial Agents and Chemotherapy.

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

R. Moots, Mahboob Rahman, S. Kotak, 2017, PloS one.

A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis

P. Perić, J. Korth-Bradley, R. Pedersen, 2018, European journal of rheumatology.

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

R. Moots, Mahboob Rahman, S. Kotak, 2017, PloS one.

Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody‐Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse

M. Berger, J. Korth-Bradley, S. P. King, 2001, Journal of clinical pharmacology.

Pancreatitis in tigecycline Phase 3 and 4 clinical studies

M. Wible, J. Korth-Bradley, P. Mcgovern, 2013, The Journal of antimicrobial chemotherapy.

How to Fix the Dangerous Lack of Clinical Pharmacology Education in the Medical Profession: The Generation of Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency

J. Korth-Bradley, V. Donnenberg, P. Wiernik, 2016, Journal of clinical pharmacology.

Regulatory Framework for Drug Development in Rare Diseases

J. Korth-Bradley, 2022, Journal of clinical pharmacology.

Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts

Kyle T. Matschke, J. Korth-Bradley, I. Bhattacharya, 2012, European Journal of Clinical Pharmacology.

Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with Tigecycline

J. Korth-Bradley, S. Bhavnani, P. Ambrose, 2011, Antimicrobial Agents and Chemotherapy.

Comparative bioavailability study of single-dose film-coated and sugar-coated ethionamide tablets in healthy volunteers.

J. Korth-Bradley, H. Tucker, D. Mansfield, 2014, Clinical therapeutics.

Long‐term evaluation of analytical methods used in sirolimus therapeutic drug monitoring

G. Horowitz, D. Holt, D. Mandelbrot, 2014, Clinical transplantation.

Absence of a Pharmacokinetic Interaction between Etanercept and Warfarin

A. Patat, Honghui Zhou, J. Korth-Bradley, 2004, Journal of clinical pharmacology.

Impact of Different Factors on the Probability of Clinical Response in Tigecycline-Treated Patients with Intra-Abdominal Infections

G. Drusano, J. Korth-Bradley, S. Bhavnani, 2009, Antimicrobial Agents and Chemotherapy.

Evaluation of Pharmacokinetic Interaction Between Bromfenac and Phenytoin in Healthy Males

W. Cevallos, J. Korth-Bradley, S. Decleene, 1997, Journal of clinical pharmacology.

Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis.

W. Cevallos, J. Korth-Bradley, S. Decleene, 1996, The Journal of rheumatology.

The Education of Prescribers for Safe and Effective Use of Medications

J. Korth-Bradley, 2018, Clinical pharmacology and therapeutics.

Interrupted Time Series Analysis in Clinical Research

L. Matowe, J. Korth-Bradley, C. Crivera, 2003, The Annals of pharmacotherapy.

Pharmacokinetics of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors

C. Punt, J. Boni, J. Korth-Bradley, 2001 .

Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis.

P. Walson, J. Boni, D. Simcoe, 1999, Clinical therapeutics.

The Clinical Pharmacist as Principal Investigator: A Commentary from the American College of Clinical Pharmacy

M. Munger, D. Knoell, J. Korth-Bradley, 2000, Pharmacotherapy.

Absence of a Clinically Relevant Interaction Between Etanercept and Digoxin

A. Patat, D. Simcoe, Honghui Zhou, 2004, Journal of clinical pharmacology.

Assessment of the Effects of Age and Renal Function on Pharmacokinetics of Bazedoxifene in Postmenopausal Women

J. Korth-Bradley, J. Ermer, W. McKeand, 2018, Clinical pharmacology in drug development.

Hospital-Acquired Pneumonia Imipenem-Cilastatin for Treatment of Tigecycline Regimens versus Clinical Efficacy of Two High-Dosage Randomized Phase 2 Trial To Evaluate the

J. Ramirez, Jeany Q. Li, J. Korth-Bradley, 2013 .

Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts

Kyle T. Matschke, J. Korth-Bradley, I. Bhattacharya, 2011, European Journal of Clinical Pharmacology.

Effects of Age and Gender on the Pharmacokinetics of Bromfenac in Healthy Volunteers

J. Boni, W. Cevallos, J. Korth-Bradley, 1997, The Annals of pharmacotherapy.

Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects

Kyle T. Matschke, J. Korth-Bradley, Ashesh Gandhi, 2014, Journal of clinical pharmacology.

Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects

L. Valentino, J. Korth-Bradley, I. Elezović, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.